Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$180.4 million.

  • Ultragenyx Pharmaceutical's Net Income towards Common Stockholders fell 3512.46% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$581.2 million, marking a year-over-year decrease of 397.38%. This contributed to the annual value of -$570.6 million for FY2024, which is 594.82% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Net Income towards Common Stockholders stood at -$180.4 million, which was down 3512.46% from -$115.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Net Income towards Common Stockholders registered a high of -$73.0 million during Q3 2021, and its lowest value of -$245.1 million during Q3 2022.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$151.1 million (2025), whereas its average is -$146.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 58361.84% in 2021, then soared by 3486.53% in 2023.
  • Ultragenyx Pharmaceutical's Net Income towards Common Stockholders (Quarter) stood at -$124.8 million in 2021, then decreased by 24.34% to -$155.2 million in 2022, then increased by 20.6% to -$123.2 million in 2023, then decreased by 9.39% to -$134.8 million in 2024, then tumbled by 33.88% to -$180.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$180.4 million for Q3 2025, versus -$115.0 million for Q2 2025 and -$151.1 million for Q1 2025.